A Little-Known Drug Company Could Have The Answer For Some Alzheimer's Patients
Alzheon plans to start a multi-center (U.S. and international) Phase 3 trial in 500 mild APOE4/4 homozygous patients next year, with a second trial to start about six months later. Tolar estimates that 10-15% of all AD patients (about 530,000 people) are APOE4/4 homozygotes. Given that these are the patients with the highest prevalence of